Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX), a pioneering radiopharmaceutical company, has announced its participation in two upcoming investor conferences in August 2024. The company's senior leadership team will be available for one-on-one meetings with investors at both events.

The first conference is the BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024, which will be held virtually. The second is the 2024 Wedbush PacGrow Healthcare Conference, taking place in-person in New York, NY on August 13-14, 2024.

At the Wedbush conference, Perspective Therapeutics will also participate in a panel discussion titled 'Nuke 'em From Orbit: Radiotherapy' at 9:30am ET. This engagement highlights the company's focus on advanced treatment applications for cancers throughout the body using radiopharmaceuticals.

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.

BTIG Virtual Biotechnology Conference 2024
Date: August 5-6, 2024
Location: Virtual

2024 Wedbush PacGrow Healthcare Conference
Date: August 13-14, 2024
Location: New York, NY (in-person only)

Panel Discussion - Nuke ‘em From Orbit: Radiotherapy
Time: 9:30am ET

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

FAQ

What investor conferences will Perspective Therapeutics (CATX) attend in August 2024?

Perspective Therapeutics (CATX) will participate in two investor conferences in August 2024: the BTIG Virtual Biotechnology Conference on August 5-6, and the 2024 Wedbush PacGrow Healthcare Conference on August 13-14 in New York, NY.

Will Perspective Therapeutics (CATX) present at the Wedbush PacGrow Healthcare Conference?

Yes, Perspective Therapeutics (CATX) will participate in a panel discussion titled 'Nuke 'em From Orbit: Radiotherapy' at 9:30am ET during the Wedbush PacGrow Healthcare Conference on August 13-14, 2024.

Is the BTIG Virtual Biotechnology Conference 2024 an in-person event for Perspective Therapeutics (CATX)?

No, the BTIG Virtual Biotechnology Conference 2024, scheduled for August 5-6, is a virtual event where Perspective Therapeutics (CATX) will participate remotely.

What type of meetings will Perspective Therapeutics (CATX) offer at the August 2024 investor conferences?

Perspective Therapeutics (CATX) will offer one-on-one meetings with investors at both the BTIG Virtual Biotechnology Conference and the 2024 Wedbush PacGrow Healthcare Conference in August 2024.